This week in drug discovery (21-25 April)
News round-up for 21-25 April by DDW Senior Digital Content Editor Diana Spencer.
With Eli Lilly so far winning the race to bring an oral GLP-1 drug to market, having announced positive topline results from a Phase III trial, this week our news highlights focus on clinical studies.
The top stories:
Lilly’s oral GLP-1 first to complete a Phase III trial
Eli Lilly has announced positive topline Phase III results from ACHIEVE-1, evaluating the safety and efficacy of orforglipron compared to placebo in adults with type 2 diabetes and inadequate glycaemic control with diet and exercise alone.
Phase II trial starts for CAR-T therapy in T-cell lymphoma
March Biosciences (March Bio) announced that the first patient has been dosed in its Phase II clinical trial evaluating MB-105, a first-in-class CD5-targeted CAR-T cell therapy for patients with relapsed or refractory CD5-positive T-cell lymphoma.
Medicus extends Phase II study in nodular basal cell carcinoma
Medicus Pharma has announced plans to extend its SKNJCT-003 Phase II clinical study for the treatment of nodular basal cell carcinoma (BCC).
AACR data shows promise for patients with solid tumour types
Data from the Friends of Cancer Research’s (Friends’) ctMoniTR Project, recently published in Clinical Cancer Research (CCR), demonstrate a strong association between changes in levels of circulating tumour DNA (ctDNA) and treatment outcomes.
UMass joins Phase II trial for multiple sclerosis
The University of Massachusetts (UMass) has begun dosing participants with Tiziana Life Sciences’ lead development candidate, intranasal foralumab, as part of an ongoing Phase II trial in patients with non-active secondary progressive multiple sclerosis (na-SPMS).
